$ORKA News
Last published 3d ago
- 3d agoORKAOruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last
- 3d agoORKAOruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
- 1w agoORKAOruka Therapeutics to Participate in Multiple Upcoming ConferencesGlobeNewswireMENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the
- 2w agoORKAOruka Therapeutics Presentation of Interim EVERLAST-B Data - ORUKA THERAPEUTICS INCEarnings Call TranscriptsThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Uruka Therapeutics presentation of Interim Everlast B data. All lines have been
- 2w agoORKAOruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe PsoriasisGlobeNewswire61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to
- 2w agoORKAOruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026GlobeNewswireMENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the
- 2mo agoORKAOruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare ConferenceGlobeNewswireMENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the
- 2mo agoORKAOruka Therapeutics Appoints Todd Edwards as Chief Commercial OfficerGlobeNewswireMENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the
- 3mo agoORKAOruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026Phase 3 program
- 5mo agoORKAORUKA THERAPEUTICS, INC. - JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - ORUKA THERAPEUTICS INCEarnings Call TranscriptsWelcome, everyone, to Jefferies' 2026 Global Healthcare Conference. My name is Roger Song, senior analyst, covers Semicat Biotech. It is my great pleasure to have the next conversation with Ruka Therapeutics, and then we
- 5mo agoABVXORKASYREPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationGlobeNewswireDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech
- 5mo agoORKAOruka Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireMENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 6mo agoORKAOruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected
- 6mo agoACHVEWTXORKAAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaGlobeNewswireSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 6mo agoHALOORKAHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's...
- 6mo agoORKAOruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingGlobeNewswireMENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and
- 6mo agoORKAOruka Therapeutics Announces Proposed $500 Million Underwritten Public OfferingGlobeNewswireMENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and
- 6mo agoORKAOruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque PsoriasisGlobeNewswireORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term
- 6mo agoORKAOruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026GlobeNewswireMENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the
- 8mo agoORKAOruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected
- 9mo agoORKAOruka Therapeutics to Participate in Multiple Upcoming ConferencesGlobeNewswireMENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 10mo agoORKAOruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001GlobeNewswireORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected
- 11mo agoORKAOruka Therapeutics Announces New Board Member and Board TransitionGlobeNewswireMENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 1y agoORKAOruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts:
- 1y agoORKAOruka Therapeutics to Present at Multiple November Investor ConferencesGlobeNewswireMENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the
- 1y agoORKAOruka Therapeutics Announces $180 Million Private PlacementGlobeNewswireMENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka" or the "Company") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the
- 1y agoORKAOruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001GlobeNewswireHalf-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment
- 1y agoORKAOruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireFirst patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing,
- 1y agoORKAOruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in SeptemberGlobeNewswireIND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral
- 1y agoORKAOruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating OfficerGlobeNewswireMENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 1y agoORKAOruka Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireMENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 1y agoORKAOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F AntibodyGlobeNewswirePharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per
- 1y agoORKAOruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireContinued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H
- 1y agoORKAOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceGlobeNewswireMENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the
- 1y agoORKAOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingGlobeNewswireHalf-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar
- 1y agoORKAOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple
- 1y agoORKAOruka Therapeutics to Present at Multiple March Investor ConferencesGlobeNewswireMENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment
- 1y agoORKAOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyGlobeNewswirePharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected
- 1y agoORKANBIOruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireMENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic
- 1y agoORKAOruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare ConferenceGlobeNewswireMENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic
- 1y agoORKAOruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSuccessful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data,
- 2y agoORKAOruka Therapeutics to Present at Multiple November Investor ConferencesGlobeNewswireMENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic
- 2y agoORKAOruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressGlobeNewswireHalf-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding affinity and epitope
- 2y agoORKAOruka Therapeutics Announces $200 Million Private PlacementGlobeNewswireMENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka" or the "Company") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the
- 2y agoORKAOruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19GlobeNewswireORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing now expected
- 2y agoORKAOruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 MillionGlobeNewswireOruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to advance co-lead